CN101679962A - 单链环状rna及制备该单链环状rna的方法 - Google Patents
单链环状rna及制备该单链环状rna的方法 Download PDFInfo
- Publication number
- CN101679962A CN101679962A CN200880015108A CN200880015108A CN101679962A CN 101679962 A CN101679962 A CN 101679962A CN 200880015108 A CN200880015108 A CN 200880015108A CN 200880015108 A CN200880015108 A CN 200880015108A CN 101679962 A CN101679962 A CN 101679962A
- Authority
- CN
- China
- Prior art keywords
- rna
- strand
- nucleotide
- sequence
- circular rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (11)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007125045A JP5296328B2 (ja) | 2007-05-09 | 2007-05-09 | 1本鎖環状rnaおよびその製造方法 |
JP125045/2007 | 2007-05-09 | ||
PCT/JP2008/058990 WO2008140126A1 (ja) | 2007-05-09 | 2008-05-09 | 1本鎖環状rnaおよびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101679962A true CN101679962A (zh) | 2010-03-24 |
Family
ID=40002313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880015108A Pending CN101679962A (zh) | 2007-05-09 | 2008-05-09 | 单链环状rna及制备该单链环状rna的方法 |
Country Status (26)
Country | Link |
---|---|
US (3) | US20100137407A1 (zh) |
EP (1) | EP2143792B1 (zh) |
JP (1) | JP5296328B2 (zh) |
KR (1) | KR101525633B1 (zh) |
CN (1) | CN101679962A (zh) |
AR (1) | AR072034A1 (zh) |
AU (1) | AU2008250075B2 (zh) |
BR (1) | BRPI0811440A2 (zh) |
CA (1) | CA2685994A1 (zh) |
CO (1) | CO6241167A2 (zh) |
CY (1) | CY1115283T1 (zh) |
DK (1) | DK2143792T3 (zh) |
ES (1) | ES2446040T3 (zh) |
HK (1) | HK1135140A1 (zh) |
HR (1) | HRP20140170T1 (zh) |
IL (1) | IL201975A (zh) |
MX (1) | MX2009011101A (zh) |
MY (1) | MY154495A (zh) |
NZ (1) | NZ581251A (zh) |
PL (1) | PL2143792T3 (zh) |
PT (1) | PT2143792E (zh) |
RU (1) | RU2523596C2 (zh) |
SI (1) | SI2143792T1 (zh) |
TW (1) | TWI468515B (zh) |
UA (1) | UA101806C2 (zh) |
WO (1) | WO2008140126A1 (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102918156A (zh) * | 2010-07-08 | 2013-02-06 | 株式会社博纳克 | 用于控制基因表达的单链核酸分子 |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
CN105063210A (zh) * | 2015-08-12 | 2015-11-18 | 中国农业科学院北京畜牧兽医研究所 | 一种环状rna的鉴定方法 |
US9200278B2 (en) | 2010-08-03 | 2015-12-01 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
CN107557363A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院上海生命科学研究院 | 可诱导型siRNA表达载体及其制备和应用 |
CN108251424A (zh) * | 2017-12-19 | 2018-07-06 | 天利康(天津)科技有限公司 | 一种单链环状rna和dna及其制备方法和应用 |
US10238752B2 (en) | 2012-05-26 | 2019-03-26 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
US10612020B2 (en) | 2013-12-26 | 2020-04-07 | Tokyo Medical University | Artificial mimic miRNA for controlling gene expression, and use of same |
CN111201319A (zh) * | 2017-10-11 | 2020-05-26 | 日东电工株式会社 | 核酸分子表达的调节 |
CN111344407A (zh) * | 2017-09-15 | 2020-06-26 | 联邦科学技术研究组织 | Rna分子 |
US10934542B2 (en) | 2013-12-27 | 2021-03-02 | Bonac Corporation | Artificial match-type miRNA for controlling gene expression and use therefor |
US11027023B2 (en) | 2014-12-27 | 2021-06-08 | Bonac Corporation | Natural type miRNA for controlling gene expression, and use of same |
US11142769B2 (en) | 2015-03-27 | 2021-10-12 | Bonac Corporation | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability |
WO2023024500A1 (en) * | 2021-08-27 | 2023-03-02 | Peking University | Constructs and methods for preparing circular rna |
CN115786374A (zh) * | 2022-07-06 | 2023-03-14 | 广州吉赛生物科技股份有限公司 | 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法 |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009102081A1 (ja) * | 2008-02-15 | 2009-08-20 | Riken | 環状1本鎖核酸複合体およびその製造方法 |
SG185544A1 (en) * | 2010-05-14 | 2012-12-28 | Fluidigm Corp | Nucleic acid isolation methods |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
SG190679A1 (en) | 2010-10-01 | 2013-07-31 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
US9115167B2 (en) * | 2011-03-10 | 2015-08-25 | Biomics Biotechnologies Co., Ltd. | Multi-targets interfering RNA molecules and their applications |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
SG11201401196WA (en) | 2011-10-03 | 2014-05-29 | Moderna Therapeutics Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013077446A1 (ja) * | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
JP6296434B2 (ja) * | 2013-01-25 | 2018-03-20 | 国立研究開発法人理化学研究所 | 機能性核酸分子の構築法 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP2996697B1 (en) * | 2013-05-15 | 2019-06-26 | Robert Kruse | Intracellular translation of circular rna |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CN104419704B (zh) * | 2013-09-05 | 2016-09-14 | 中国科学院上海生命科学研究院 | 一种内含子来源环形rna分子及其成环关键核酸序列的应用 |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
JPWO2018182008A1 (ja) | 2017-03-31 | 2020-02-06 | 株式会社ボナック | 遺伝子発現制御機能を有する環状型核酸分子 |
EP3617314B1 (en) | 2017-04-28 | 2023-02-15 | Kyowa Kirin Co., Ltd. | Oligonucleotide derivative or salt thereof |
US11756183B2 (en) | 2017-06-23 | 2023-09-12 | Cornell University | RNA molecules, methods of producing circular RNA, and treatment methods |
BR112020011670A2 (pt) | 2017-12-15 | 2020-11-17 | Flagship Pioneering Innovations Vi, Llc. | composições compreendendo polirribonucleotídeos circulares e seus usos |
EP3778886A4 (en) * | 2018-03-30 | 2022-11-02 | Toray Industries, Inc. | METHOD FOR PRODUCING A HAIRPIN SINGLE-STRANDED RNA MOLECULE |
WO2019236673A1 (en) | 2018-06-06 | 2019-12-12 | Massachusetts Institute Of Technology | Circular rna for translation in eukaryotic cells |
CN113543770A (zh) | 2019-03-01 | 2021-10-22 | 旗舰创业创新第六有限责任公司 | 用于递送多核糖核苷酸的组合物、方法和试剂盒 |
IL285951B1 (en) | 2019-03-01 | 2024-04-01 | Flagship Pioneering Innovations Vi Llc | Polyribonucleotides and their cosmetic uses |
CA3128626A1 (en) | 2019-03-04 | 2020-09-10 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides and pharmaceutical compositions thereof |
JP2022527763A (ja) | 2019-03-25 | 2022-06-06 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 修飾環状ポリリボヌクレオチドを含む組成物及びその使用 |
CN115867291A (zh) | 2019-05-22 | 2023-03-28 | 麻省理工学院 | 环状rna组合物和方法 |
EP3983539A1 (en) | 2019-06-14 | 2022-04-20 | Flagship Pioneering Innovations VI, LLC | Circular rnas for cellular therapy |
EP3987038A1 (en) | 2019-06-19 | 2022-04-27 | Flagship Pioneering Innovations VI, LLC | Methods of dosing circular polyribonucleotides |
US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
ES2961245T3 (es) | 2019-12-04 | 2024-03-11 | Orna Therapeutics Inc | Composiciones y métodos de ARN circular |
TW202142689A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 用於轉譯之組合物及其使用方法 |
TW202142239A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 包含環狀多核糖核苷酸之組合物之遞送 |
EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
EP4153224A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Coronavirus antigen compositions and their uses |
WO2021236952A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
WO2022191642A1 (ko) | 2021-03-10 | 2022-09-15 | 알지노믹스 주식회사 | 자가 환형화 rna 구조체 |
AU2022397300A1 (en) | 2021-11-24 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and their uses |
WO2023096990A1 (en) | 2021-11-24 | 2023-06-01 | Flagship Pioneering Innovation Vi, Llc | Coronavirus immunogen compositions and their uses |
IL312799A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions of varicella-zoster virus and uses thereof |
CA3240691A1 (en) | 2021-12-17 | 2023-06-22 | Alexandra Sophie DE BOER | Methods for enrichment of circular rna under denaturing conditions |
TW202340461A (zh) | 2021-12-22 | 2023-10-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物和方法 |
WO2023122789A1 (en) | 2021-12-23 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
CN116694638A (zh) * | 2023-02-20 | 2023-09-05 | 天津微环生物医药科技有限责任公司 | 环状核酸应用-miRNA抑制剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138166A1 (en) * | 2002-12-31 | 2004-07-15 | Damha Masad J. | Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11137260A (ja) | 1997-11-06 | 1999-05-25 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス環状ダンベル型rna−dnaキメラ化合物及び抗インフルエンザウイルス剤 |
US6210931B1 (en) * | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
BR0009884A (pt) * | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
RU2322500C2 (ru) * | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20090247606A1 (en) * | 2001-08-28 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP1430157B1 (en) * | 2002-02-20 | 2011-08-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS C VIRUS (HCV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
AU2003220136A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20070105108A1 (en) * | 2003-06-25 | 2007-05-10 | Somagenics, Inc. | Polynucleotides capable of target-depedent circularization and topological linkage |
US7972816B2 (en) * | 2003-08-08 | 2011-07-05 | National Institute Of Advanced Industrial Science And Technology | Efficient process for producing dumbbell DNA |
WO2006007569A2 (en) * | 2004-07-01 | 2006-01-19 | Somagenics, Inc. | Methods of preparation of gene-specific oligonucleotide libraries and uses thereof |
-
2007
- 2007-05-09 JP JP2007125045A patent/JP5296328B2/ja not_active Expired - Fee Related
-
2008
- 2008-05-07 AR ARP080101917A patent/AR072034A1/es unknown
- 2008-05-09 CN CN200880015108A patent/CN101679962A/zh active Pending
- 2008-05-09 SI SI200831175T patent/SI2143792T1/sl unknown
- 2008-05-09 US US12/598,974 patent/US20100137407A1/en not_active Abandoned
- 2008-05-09 DK DK08764303.7T patent/DK2143792T3/da active
- 2008-05-09 EP EP08764303.7A patent/EP2143792B1/en active Active
- 2008-05-09 PT PT87643037T patent/PT2143792E/pt unknown
- 2008-05-09 CA CA002685994A patent/CA2685994A1/en not_active Abandoned
- 2008-05-09 TW TW97117329A patent/TWI468515B/zh not_active IP Right Cessation
- 2008-05-09 NZ NZ581251A patent/NZ581251A/en not_active IP Right Cessation
- 2008-05-09 ES ES08764303.7T patent/ES2446040T3/es active Active
- 2008-05-09 WO PCT/JP2008/058990 patent/WO2008140126A1/ja active Application Filing
- 2008-05-09 RU RU2009145502/10A patent/RU2523596C2/ru not_active IP Right Cessation
- 2008-05-09 UA UAA200912771A patent/UA101806C2/ru unknown
- 2008-05-09 PL PL08764303T patent/PL2143792T3/pl unknown
- 2008-05-09 AU AU2008250075A patent/AU2008250075B2/en not_active Ceased
- 2008-05-09 MX MX2009011101A patent/MX2009011101A/es active IP Right Grant
- 2008-05-09 MY MYPI20094697A patent/MY154495A/en unknown
- 2008-05-09 BR BRPI0811440-4A2A patent/BRPI0811440A2/pt not_active IP Right Cessation
- 2008-05-09 KR KR1020097025654A patent/KR101525633B1/ko not_active IP Right Cessation
-
2009
- 2009-11-05 IL IL201975A patent/IL201975A/en not_active IP Right Cessation
- 2009-12-09 CO CO09140877A patent/CO6241167A2/es not_active Application Discontinuation
-
2010
- 2010-03-25 HK HK10103140.1A patent/HK1135140A1/xx not_active IP Right Cessation
-
2014
- 2014-02-25 HR HRP20140170AT patent/HRP20140170T1/hr unknown
- 2014-03-24 CY CY20141100228T patent/CY1115283T1/el unknown
-
2017
- 2017-08-21 US US15/681,884 patent/US20180073020A1/en not_active Abandoned
-
2018
- 2018-12-28 US US16/235,656 patent/US20190292538A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040138166A1 (en) * | 2002-12-31 | 2004-07-15 | Damha Masad J. | Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
CN104818276A (zh) * | 2010-07-08 | 2015-08-05 | 株式会社博纳克 | 用于控制基因表达的单链核酸分子 |
CN104818276B (zh) * | 2010-07-08 | 2020-12-11 | 株式会社博纳克 | 用于控制基因表达的单链核酸分子 |
CN102918156B (zh) * | 2010-07-08 | 2015-11-25 | 株式会社博纳克 | 用于控制基因表达的单链核酸分子 |
CN102918156A (zh) * | 2010-07-08 | 2013-02-06 | 株式会社博纳克 | 用于控制基因表达的单链核酸分子 |
US9200278B2 (en) | 2010-08-03 | 2015-12-01 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
US9206422B2 (en) | 2010-08-03 | 2015-12-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
US10238752B2 (en) | 2012-05-26 | 2019-03-26 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
US10612020B2 (en) | 2013-12-26 | 2020-04-07 | Tokyo Medical University | Artificial mimic miRNA for controlling gene expression, and use of same |
US10934542B2 (en) | 2013-12-27 | 2021-03-02 | Bonac Corporation | Artificial match-type miRNA for controlling gene expression and use therefor |
US11027023B2 (en) | 2014-12-27 | 2021-06-08 | Bonac Corporation | Natural type miRNA for controlling gene expression, and use of same |
US11142769B2 (en) | 2015-03-27 | 2021-10-12 | Bonac Corporation | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability |
CN105063210A (zh) * | 2015-08-12 | 2015-11-18 | 中国农业科学院北京畜牧兽医研究所 | 一种环状rna的鉴定方法 |
CN107557363A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院上海生命科学研究院 | 可诱导型siRNA表达载体及其制备和应用 |
CN107557363B (zh) * | 2016-06-30 | 2021-03-12 | 中国科学院分子细胞科学卓越创新中心 | 可诱导型siRNA表达载体及其制备和应用 |
CN111344407A (zh) * | 2017-09-15 | 2020-06-26 | 联邦科学技术研究组织 | Rna分子 |
CN111201319A (zh) * | 2017-10-11 | 2020-05-26 | 日东电工株式会社 | 核酸分子表达的调节 |
CN108251424A (zh) * | 2017-12-19 | 2018-07-06 | 天利康(天津)科技有限公司 | 一种单链环状rna和dna及其制备方法和应用 |
WO2023024500A1 (en) * | 2021-08-27 | 2023-03-02 | Peking University | Constructs and methods for preparing circular rna |
CN115786374A (zh) * | 2022-07-06 | 2023-03-14 | 广州吉赛生物科技股份有限公司 | 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法 |
CN115786374B (zh) * | 2022-07-06 | 2023-10-13 | 广州吉赛生物科技股份有限公司 | 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101679962A (zh) | 单链环状rna及制备该单链环状rna的方法 | |
EP1552018B1 (en) | Methods and compositions relating to gene silencing | |
JP6325974B2 (ja) | Rna干渉を媒介する短鎖rna分子 | |
Gaynor et al. | RNA interference: a chemist's perspective | |
WO2005079533A2 (en) | Methods and compositions for mediating gene silencing | |
AU2003299970A1 (en) | Rna interference | |
CN1867672B (zh) | 改良的siRNA分子和应用该改良的siRNA分子的抑制基因表达的方法 | |
Chalupnikova et al. | Production and application of long dsRNA in mammalian cells | |
Crater et al. | Evaluation of the ability of short and long double-stranded RNAs to induce homologous gene silencing in the protozoan parasite, Toxoplasma gondii | |
Murray et al. | Efficient RNAi-induced protein knockdown in somatic cells using diced or chemically produced small interfering RNAs (siRNA) | |
Karpilow et al. | siRNA: enhanced functionality through rational design and chemical modification | |
Bertrand et al. | Short double-stranded ribonucleic acid as inhibitor of gene expression by the interference mechanism | |
Papik | An apoptosis directed multi-target approach for therapeutic siRNA oligonucleotides | |
Liu et al. | Ribozyme targeted the point-mutation of activated oncogene inhibits its expression in vivo | |
Manual | siIMPORTER™ | |
Alembekov et al. | Efficiency of the RNA interference induced by the genetic constructs expressing siRNAs depends on promoter strength |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: OTSUKA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: OTSUKA PHARMACEUTICAL CO., LTD. HAYASHI KASEI CO., LTD. Effective date: 20140925 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20140925 Address after: Saitama Prefecture of Japan and the city of light Applicant after: Independent Administrative Institution Physical Chemistry Institute Applicant after: Otsuka Pharmaceutical Co., Ltd. Address before: Saitama Prefecture, Japan Applicant before: Independent Administrative Institution Physical Chemistry Institute Applicant before: Otsuka Pharmaceutical Co., Ltd. Applicant before: Hayashi Kasei Co., Ltd. |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20170315 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |